33252-32-3

Basic information

• Product Name: 2-Amino-4-ethylpyridine
• Synonyms: (4-Ethylpyridin-2-yl)aMine;2-PyridinaMine, 4-ethyl-;33252-32-3;4-ETHYLPYRIDIN-2-AMINE;2-AMINO-4-ETHYLPYRIDINE;4-ETHYL-2-PYRIDINAMINE
• CAS NO: 33252-32-3
• Molecular Formula: C₇H₁₀N₂
• Molecular Weight: 122.17
• EINECS: 251-430-2
• Product Categories: Pyrroles ,Pyrimidines;pharmacetical;Pyridine;Aromatics Compounds;Aromatics;Drug Analogues;Intermediates;Amines;Heterocycles
• Mol File: 33252-32-3.mol

Chemical Properties

• Melting Point: 50-52°C
• Boiling Point: 100-103°C/4 mm
• Flash Point: 123.479 °C
• Appearance: White crystalline powder
• Density: 1.037 g/cm³
• Vapor Pressure: 0.0345mmHg at 25°C
• Refractive Index: 1.56
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• Solubility: Hexane, Ethyl Acetate, Methyl tert-Butyl Ether
• PKA: 7.29±0.11(Predicted)
• Water Solubility: Soluble in water, hexane, ethyl acetate and methyl tert-butyl ether.
• CAS DataBase Reference: 2-Amino-4-ethylpyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Amino-4-ethylpyridine(33252-32-3)
• EPA Substance Registry System: 2-Amino-4-ethylpyridine(33252-32-3)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 36/37/38-20/21/22-41-37/38-22
• Safety Statements: 26-36/37/39-36-39
• RIDADR: UN2811
• HazardClass: 6.1
• PackingGroup: III
• Hazardous Substances Data: 33252-32-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-Amino-4-ethylpyridine is used as a precursor for the preparation of 1-ethyl-3-[5-(7-ethyl-imidazo[1,2-a]pyridin-2-yl)-2-hydroxy-phenyl]-urea, a compound with potential applications in the development of new pharmaceuticals. It serves as an intermediate in organic synthesis, playing a crucial role in the creation of complex molecules for various therapeutic purposes.
Used as an Antibiotic Analogue:
2-Amino-4-ethylpyridine is also recognized as an analogue of pirlimycin, an antibiotic with antimicrobial properties. This characteristic makes it a valuable compound in the development of new antibiotics to combat resistant bacterial strains and improve treatment options for various infections.

InChI:InChI=1/C7H10N2/c1-2-6-3-4-9-7(8)5-6/h3-5H,2H2,1H3,(H2,8,9)

Upstream product

• 536-75-4 4-Ethylpyridine 
• 95337-79-4 2-(2,5-dimethylpyrrol-1-yl)-4-ethylpyridine 
• 14906-55-9 4-ethylpyridine-1-oxide 
• 695-34-1 2-Amino-4-methylpyridine 
• 102000-55-5 4-vinylpyridin-2-amine 
• 19798-80-2 2-Amino-4-chloropyridine 
• 95337-78-3 2-(2,5-dimethyl-pyrrol-1-yl)-4-methyl-pyridine 

Downstream Products

• 70936-17-3 4-ethyl-5-nitropyridin-2-amine 
• 70936-16-2 2-amino-3-nitro-4-ethylpyridine 
• 54453-91-7 2-bromo-4-ethylpyridine 
• 103823-77-4 1-Ethyl-3-[5-(7-ethyl-imidazo[1,2-a]pyridin-2-yl)-2-hydroxy-phenyl]-urea 
• 128618-46-2 2-[(E)-2-(3-Benzyloxy-4-nitro-phenyl)-vinyl]-7-ethyl-3-methyl-imidazo[1,2-a]pyridine 
• 477878-38-9 2-[[(4-ethylpyridin-2-yl)imino]methyl]-phenol 
• 128618-65-5 2-[2-(4-Amino-3-hydroxyphenyl)ethyl]-7-ethyl-3-methylimidazo[1,2-a]pyridine 
• 92486-38-9 2-cyano-4-ethylpyridine 
• 59576-27-1 2-acetyl-4-ethylpyridine 
• 3052-28-6 4,4′-diethyl-2,2′-bipyridine 
• 1228304-03-7 2-(4-bromophenyl)-7-ethylimidazo[1,2-a]pyridine hydrobromide 
• 61702-05-4 bis(4-ethyl-2-pyridylimino)isoindoline 
• 1215692-48-0 C₅₇H₄₈IrN₃ 

Relevant articles and documents

A model D - amino acid oxidase inhibitor and its preparation and application

The invention provides a novel D- amino acid oxidase inhibitor and a preparation and application thereof. In particular, the invention discloses derivatives of quinoxaline-2,3-diketone, which has a novel structure shown in formula A, as well as a preparation method thereof and an application as an inhibitor of D-amino acid oxidase (DAAO). The compound provided by the invention shows excellent effects of analgesia and blocking morphine analgesia tolerance, and has application value for analgesia, treating opiate drug tolerance, and anti-schizophrenia.

The reductive cleavage of picolinic amides

Treatment of picolinic amides with excess zinc in aqueous hydrochloric acid at room temperature affords the corresponding amines in good to excellent yields. The mild reaction conditions exhibit useful functional group tolerance and facilitate the application of the picolinic amide moiety as a protecting group which can be easily introduced and selectively removed.

INHIBITORS OF BRUTON'S TYROSINE KINASE

Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. In addition, reversible inhibitors of Btk are also described. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

Substituted 2-aminopyridines as inhibitors of nitric oxide synthases.

A series of substituted 2-aminopyridines was prepared and evaluated as inhibitors of human nitric oxide synthases (NOS). 4,6-Disubstitution enhanced both potency and specificity for the inducible NOS with the most potent compound having an IC50 of 28 nM.

Protection of Primary Amines as N-Substituted 2,5-Dimethylpyrroles

Protection of primary amine group is achieved by incorporating it into an N-substituted 2,5-dimethylpyrrole system.The method affords protection against strong bases and nucleophiles, heating with concentrated alkali, standard mineral acid work-up conditions, and various other reagents.Phenyl-, pyridil-, thiazolyl-, and alkyl-amines have been studied.All give trisubstituted pyrroles in high yield (>80percent) by reaction with hexane-2,5-dione.The pyrroles from the first three types are stable to storage; even the N-alkyl compounds can be used without difficulty.Regeneration of the amine group, by treatment with hydrxylamine hydrochloride, is efficient (80percent yield) with the phenyl, pyridyl, and alkyl compounds but less satisfactory (60 - 65percent generally but down to 25percent in two cases) with the thiazolyl derivatives.